Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Mar 2017

Nakagawa Makoto, Nakatani Fumihiko, Kitabayashi Issay

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bone Neoplasms
Share to Chondrosarcoma
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 28400543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].PMID 28400543Read ↗

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?Semantic proximity Read ↗

Novel therapeutic approaches in chondrosarcoma.Semantic proximity Read ↗

IDH Mutations in Chondrosarcoma: Case Closed or Not?Semantic proximity Read ↗

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.Semantic proximity Read ↗

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Semantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity Read ↗

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaSemantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.Semantic proximity Read ↗

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in ChondrosarcomaSemantic proximity Read ↗

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells.Semantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.